This CME program will highlight recent advances in the treatment and management of patients with transthyretin amyloidosis (ATTR). The expert faculty, Nivedita Uberoi Jerath, MD, MS, will first provide an introduction to amyloidosis, including an overview of amyloid formation, pathophysiology and fibril types and associated diseases. Dr. Jerath will then discuss diagnostic approaches for transthyretin amyloidosis, including current challenges and the role of family screening in early detection of disease. To conclude, the expert faculty will analyze key results and clinical implications of recent trial data in ATTR, utilizing a case-based approach. Upon completion of this educational activity, learners will be better equipped to detect and manage patients with amyloid disease with peripheral neuropathy.
Neurologists, APPs working in neurology practices, and other healthcare professionals involved in the management of patients with amyloid disease
Review the accurate and timely diagnosis of ATTRv-PN based on clinical suspicion and guidelines-directed testing strategies.
Understand the pathophysiology of ATTR disease and the mechanistic rationale for new and emerging therapies.
Develop individualized treatment plans for ATTRv-PN based on recent clinical data, patient prognosis, a review of treatment options, an assessment of safety, and shared decision making.
ATTR Disease Review for the Neurologist: Recognizing the Disease and Making the Diagnosis
Pathophysiology and Rational Therapeutic Targets: ATTRv-PN
Individualized Treatment for ATTRv-PN Based on Patient Prognosis, Review of Therapeutic Options, Safety Assessment, and Shared Decision Making
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Nivedita Uberoi Jerath, MD, MS | Nothing to disclose. |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606